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Purified type I topoisomerase from calf thymus as well as nuclear and cytoplasmic extracts from EGF-stim- 
ulated human and mouse fibroblasts in cell culture efficiently convert supercoiled plasmid DNA to the re- 
laxed form. The purified IgG fraction from the sera of Japanese patients with the rheumatic disease sclero- 
derma were shown to inhibit this relaxation activity. Thus, these patients likely produce autoantibodies to 
topoisomerase I. In addition, the human, bovine and murine enzymes hare antigenic determinants recog- 
nixed by the antisera. 
Topoisomerase I Scleroderma anttierum Epia’ermal growth factor 
1. INTRODUCTION 2.2. Preparation of IgG fraction 
Topoisomerases are enzymes that alter the 
topological conformation of DNA; they have been 
implicated in replication, gene expression and 
chromosome segregation (review [l-3]). Type I 
topoisomerases generate transient single-strand 
nicks in duplex DNA that allow for relaxation of 
supercoiled molecules as well as other topological 
manipulations [2-51. Recently, two groups [6,7] 
have identified Scl-70, a nuclear antigen recog- 
nized by the sera of patients with diffuse scleroder- 
ma, as topoisomerase I. We have shown that the 
autoantibodies from Japanese patients neutralize 
the relaxation of supercoiled plasmid DNA and 
that they cross react with topoisomerase I from 
human, bovine and murine sources. 
IgG was purified from the sera of various pa- 
tients by ammonium sulfate precipitation and 
DEAE-cellulose column chromatography as 
described [9]. 
2.3. Cell culture 
2. MATERIALS AND METHODS 
Human fibroblasts (HFO) were grown in 
Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 20% fetal bovine serum (FBS), 
0.3 mg/ml glutamine, 100 U/ml penicillin and 
100 /rg/ml streptomycin. Swiss/3T3 mouse 
fibroblasts were grown in DMEM containing 10% 
FBS, 100 U/ml penicillin and lOOpg/ml strep- 
tomycin. Cells were grown to confluency in 10 cm 
dishes at 37°C in 5% CO2 and 100% humidity. 
EGF (Collaborative Research) was added to a final 
concentration of 15 ng/ml 6 h before harvesting 
EGF-induced Swiss/3T3 cells and 9 or 12.5 h 
before collecting HFO cells. 
2.1. Materials 
Purified calf thymus topoisomerase I was ob- 
tained from BRL (Maryland). Supercoiled plasmid 
DNA was prepared by cesium chloride/ethidium 
bromide density gradient centrifugation [8]. 
2.4. Cell fractionation 
Cells were harvested and lysed as described 
previously [lo], except intact cells were frozen at 
- 70°C for l-30 days, and HFO was lysed in 1 ml. 
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2.5. Immunoneutralization 
Either 5 ~1 of cell lysate or 10~1 of diluted calf 
thymus topoisomerase I (0.25 U/pi) were in- 
cubated in 10 mM potassium phosphate, pH 7.5, 
with various amounts of purified IgG for 30 min at 
4°C with slow rotation, in a final volume of 10 or 
20 pl. 
2.6. Topoisomerase I assay 
Relaxation activity was measured by a modifica- 
tion of previous protocols [4,11]. The reaction 
mixture contained in 20 or 40 ~1 final volume 
50 mM Tris-HCl, pH 7.8, 100 mM KCl, 10 mM 
MgC12,O. 1 mM EDTA, 1 mM 2-mercaptoethanol, 
30pg/ml BSA and 20/cg/ml supercoiled plasmid 
DNA (BpMTVdhfrHiHi3 # 1,7 kb, a derivative of 
pMTVdhfr [12]). Relaxation reactions were in- 
itiated by addition of 10 or 20~1 of concentrated 
reaction mixture to the immunoneutralization and 
incubated for 30 min at 30°C. Reactions were ter- 
minated by addition of 5 or 10 ~1 of 5% SDS, 50% 
glycerol, 0.1% bromophenol blue and 0.1% xylene 
cyanole, heated to 60°C for 2 min and cooled on 
ice. 
2.7. Electrophoresis 
Samples were loaded onto a 0.7% agarose gel 
and electrophoresed for 13-15 h at 30 V 
(2.2 V/cm) in 40 mM Tris-acetate, 1 mM EDTA 
at room temperature. The gels were stained in 
1 fig/ml ethidium bromide for 45 min, destained in 
1 mM MgS04 for 1 h, visualized on a long wave 
UV transilluminator (Ultra-violet Products) and 
photographed through Kodak Wratten filters, 
nos25 and 12, as well as 3 mm of Lucite, with a 
Polaroid MP-3 land camera using Polaroid type 57 
film [8]. 
3. RESULTS 
Type I topoisomerase activity is measured as the 
ability to relax supercoiled DNA (see [2]). The 
relaxation reaction results in the formation of a 
series of topoisomers, DNA molecules with the 
same nucleotide sequence but that differ in 
topological conformation. The relaxed molecules 
migrate slower in agarose gels due to their de- 
creased compaction [ 131. 
Fig.1 shows the relaxation of supercoiled (form 
I) plasmid DNA by 2.5 U (180 ng) of purified calf 
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Fig. 1. Inhibition of purified calf thymus topoisomerase 
I. Reactions contained in 40 /cl either no topoisomerase 
(lanes 1 and 2) or 2.5 U of topoisomerase (lanes 3-10). 
Lanes: 1 and 3, no IgG;. 4, 20pg of control IgG from 
normal human sera; 2 and 5, 20 pg of FO IgG; 6, 10 pg 
FO IgG; 7, 2pg FO IgG; 8, 1 pg FO IgG; 9,0.2/~g FO 
IgG; 10, 0.1 pg FO IgG. Nicked and relaxed molecules 
comigrate. 
thymus topoisomerase I (lane 3). Normal human 
IgG has no effect on the topoisomerase activity 
(lane 4); however, at high concentrations, 
scleroderma IgG causes a tailing of nicked (form 
II) DNA (lanes 2 and 5). In a titration of purified 
IgG from FO sera with topoisomerase I (lanes 
5-lo), inhibition first appears at 1 pg IgG and 
topoisomerase activity is completely neutralized by 
lO/~g IgG. 
IgG from MI sera have a similar response (not 
shown). A third serum, KK, inhibits topoiso- 
merase I at only 0.2 pg IgG (not shown). KK sera 
may have a higher titer of autoantibodies or the 
antibodies may have a higher affinity for the 
enzyme. 
We next examined the ability of these antibodies 
to inhibit topoisomerase I activity in crude extracts 
from EGF-stimulated human and mouse cells. We 
previously have shown that EGF induces 
topoisomerase activity in contact-inhibited 
fibroblasts [lo]. Type II topoisomerase activity 
was eliminated by omission of ATP from the reac- 
tion mixture as well as by freezing the cell pellets 
prior to lysis. The type II enzyme is, in contrast to 
topoisomerase I, ATP dependent as well as labile 
in frozen whole cells [11,14]. 
Topoisomerase I activity in the cytoplasm of 
HFO cells treated for 8 h with EGF (fig.2, lane 3) 
or in the nucleus of cells treated for 12.5 h (lane 6) 
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Fig.2. Inhibition of topoisomerase I activity in HFO 
lysates. Reactions contained in 20~1 no lysate (lane l), 
5 U of calf thymus topoisomerase I (lane 2), 5 ~1 of 
12.5 h EGF-induced HFO post-nuclear fraction (lanes 
3-S), or 5 pl of 8 h EGF-induced HFO nuclear extract 
(lanes 6-8). Lanes: 1, 2, 3 and 6, no IgG; 4 and 7, 10,~g 
control IgG; 5 and 8, 1Opg of FO IgG. 
is effectively inhibited by IgG from FO sera (lanes 
5 and 8). 
FO antibodies also recognize and inhibit the 
relaxation activity from the cytoplasm of 
Swiss/3T3 mouse cells induced by EGF for 6 h and 
from the nucleus of uninduced cells (fig.3). Im- 
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Fig.3. Inhibition of topoisomerase I activity in 
Swiss/3T3 lysates. Reactions contained in 20 ~1 no lysate 
(lane l), 2.5 U of calf thymus topoisomerase I (lane 2), 
5 pl of 6 h EGF-induced Swiss/3T3 post-nuclear 
fraction (lanes 3-5), or 5 ~1 of Swiss/3T3 nuclear extract 
(lanes 6 and 7). Lanes: 1, 2, 3 and 6, no IgG; 4, 10 pg 
control IgG; 5 and 7, 1Opg of FO IgG. 
munoblotting of cytoplasmic and nuclear extracts 
from Swiss/3T3 cells with FO IgG revealed bands 
of 100, 110 and 66 kDa, similar to the known 
molecular masses of intact mammalian topoiso- 
merase I, its phosphorylated form and its pro- 
teolytic cleavage product, respectively (not shown) 
L&5,151. 
4. DISCUSSION 
Topoisomerases are probably involved in many 
aspects of cell proliferation [ 10,16-l 91. However, 
the role of the type I eukaryotic enzyme has not 
been elucidated. The clinical significance of the 
anti-topoisomerase I antibodies in the sera of 
scleroderma patients is also not understood [6]. 
Escherichia coli [20], Saccharomyces cerevisiae 
[21,22] and Schizosaccharomyces pombe [23] 
topoisomerase I mutants are viable; but DNA syn- 
thesis is blocked during the early phase of elonga- 
tion in a temperature sensitive topoisomerase I
mutant of BALB/3T3 cells [24]. A topoisomerase- 
like activity has been found to be associated with 
the EGF receptor [25,26]. We are currently using 
the autoantibodies as a tool to study the in- 
tracellular localization and regulation of 
topoisomerase I in EGF-induced cells in order to 
provide greater insight into mitogenic signal 
transduction as well as topoisomerase I function. 
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